Ibogaine offers new hope for kratom users amid bans

Ibogaine by David Dardashti is proposing a novel treatment approach for kratom users affected by increasing global bans, according to a recent press release. As regulatory actions against kratom intensify, many users are left grappling with withdrawal and dependency issues. The treatment, developed at Dardashti's facility in Playa del Carmen, Mexico, aims to provide a rapid medical exit strategy using ibogaine.

What the treatment involves

The treatment protocol employs ibogaine to reset central nervous system receptors, effectively clearing alkaloid binding sites in a single session. This approach is designed to eliminate physical cravings without leading patients into long-term pharmaceutical dependencies, unlike traditional Medication-Assisted Treatment (MAT) options. The clinic uses proprietary mathematical modeling software to tailor the ibogaine dosing to each patient's specific needs, ensuring safety and efficacy through continuous cardiac monitoring.

Regulatory context

David Dardashti is also advocating for the expansion of "Right to Try" policies in the United States, which would allow treatment-resistant patients to access regulated ibogaine therapy domestically. This initiative aligns with existing policies in countries like New Zealand and South Africa, where ibogaine is recognized as a prescription medicine. In Canada and Australia, ibogaine is regulated under prescription drug lists and Schedule 4 medical standards, respectively. The United Kingdom controls ibogaine under the Psychoactive Substances Act.

Why it matters

The legal status of kratom varies significantly across countries, creating challenges for users and healthcare providers. In Australia, kratom is banned under Schedule 9, while the UK prohibits its supply. Canada forbids sales for internal consumption, whereas New Zealand regulates it by prescription. Dardashti's call for international cooperation aims to standardize the legal and logistical frameworks for ibogaine treatment, potentially offering a safer alternative to prohibition.

"Prohibition without a medically viable off-ramp creates immediate public health emergencies," Dardashti stated. By combining precise dosing with progressive "Right to Try" policies, he believes global health leaders can offer a safe, permanent solution for those affected by shifting substance regulations.

Conclusion

Founded in 2010, Ibogaine by David Dardashti continues to innovate in the field of addiction treatment, leveraging data-driven methodologies to offer effective solutions for substance dependency. The clinic's mission is to empower individuals to overcome addiction without long-term pharmaceutical reliance, providing a promising alternative for those impacted by global kratom bans.